{
  "id": 12759088,
  "title": "BillionToOne SVP sells $297,995 in stock",
  "url": "https://urgent.news/2026/10/08/billiontoone-svp-sells-297-995-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T01:50:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/billiontoone-svp-sells-297995-in-stock-93CH-4937815"
  },
  "original_language": "en",
  "account": "John Roderick ten Bosch, the Senior Vice President of Laboratory Operations at BillionToOne, Inc., divested 2,834 shares of the company's Class A Common Stock on October 5, 2026. This sale amounted to $297,995, with each share exchanged at $105.15. The transactions were executed under a pre-established Rule 10b5-1 trading plan, which ten Bosch had established on June 2, 2026. The sale price surpassed the current stock price of $95.75, implying the stock was overvalued according to InvestingPro's data. After these transactions, ten Bosch continued to own 19,385 shares of the company. BillionToOne has shown robust financial growth, registering a 90% revenue increase and profitability in the past year, but trades at a high price-to-earnings ratio of 138. For a more thorough analysis, potential investors can consult BillionToOne's detailed Pro Research Report, exclusively available on InvestingPro. The company reported strong earnings in its second quarter, with earnings per share (EPS) of $0.15, substantially higher than the estimated $0.03. Revenue also saw a significant growth of 64%, reaching $109.4 million. Despite these positive results, the company's stock experienced a sharp decline in after-hours trading, as market participants focused on the company's future growth prospects and sustainability. Furthermore, Canaccord Genuity initiated coverage on BillionToOne, assigning a buy rating and a price target of $120.00. The firm commended the company's proprietary technologies, smNGS and QCT, which are integral to its UNITY and Northstar diagnostic portfolios. These recent activities underscore BillionToOne's solid financial performance, alongside the mixed market reaction to the latest developments. This report was produced with the assistance of AI, reviewed by an editor, and complies with the outlet's Terms and Conditions.",
  "summary": null,
  "key_points": [
    "SVP John Roderick ten Bosch sold 2,834 shares of BillionToOne stock on October 5, 2026.",
    "Sale price of $297,995 exceeded current stock price of $95.75.",
    "Ten Bosch retained 19,385 shares after the transaction."
  ],
  "editors_take": "The sale by BillionToOne's Senior Vice President of Laboratory Operations suggests insiders may be cashing in on the company's high-flying stock, despite its strong recent financial growth and bullish analyst ratings.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}